Illumina's (NASDAQ:ILMN) Genetic Analysis Tools Remain Strong

Illumina (NASDAQ:ILMN) continues to be a bullish choice of UBS (NYSE:UBS), which sees no problems with support, assuming no major disruptions come to the customer R&D funding.

UBS also sees them continuing to be led by their genetic analysis tools.

"While the stock has more than doubled this year and commands a hefty premium, our review of the competitive landscape suggests that ILMN’s position is firm. Furthermore, baring any major disruptions to customer R&D funding, demand for the company’s leading edge genetic analysis tools should remain strong...For 2010-12, we now project revenues of $894M (+34%), $1,087M (+22%), & $1,295M (+18%) and EPS of $1.06, $1.40, & $1.89, respectively, vs. our prior forecasts of $888M, $1,080M, & $1,291M and EPS of $1.04, $1.38, & $1.73," said UBS.

UBS Maintains a "Buy" on Illumina, which closed at $64.71 Monday. They have a price target of $72 on them, raising it from $60.